Post patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in brands and player...

Following the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies ...

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices follo...

Research firm PharmaTrac data shows Augmentin sales at Rs 801 crore from November 2022-23. For the month of November, Augmentin sales stood...

Lupin has been marketing Ondero and Ondero Met since 2015 in the Indian market as part of a co-marketing agreement with Boehringer Ingelhei...

State Bank of India said its board has approved Rs 10,000 crore capital raising plan through Tier I bonds. The fund raising through Additio...

Both companies entered into partnership for the sales and co-marketing of Empagliflozin and its combinations including Cospiaq (Empaglifloz...

India’s drug pricing authority has fixed prices of two key anti diabetes drugs-Sitagliptin-Metformin combination and Linagliptin-metformin ...

BI said the injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making,...

The company said the newly approved medication will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The company has received final approval from the US Food and Drug Administration (USFDA) for the medication in 300 mg strength, Zydus Cadil...

The tentatively approved abbreviated new drug application (ANDA) is therapeutically equivalent to the reference listed drug product Glyxamb...

IMS values the Indian diabetes market is at Rs9,003 crore and has recorded it as growing at 19.5%, according to a release by Lupin.

The Indian Patent Office has rejected the application of Lee Pharma for a compulsory license on AstraZeneca’s anti-diabetes drug saxaglipti...

The Kolkata Patent Office, on an opposition filed by domestic drug firm Lupin, refused the patent application on grounds that it was "obvio...

Boehringer Ingelheim will continue to sell its linagliptin under the brand names Trajenta (monotherapy) and TrajentaDuo (fixed-dose combina...

Boehringer Ingelheim India and Eli Lilly and Company India (Lilly) today said they have launched Linagliptin tablets used for treating diab...